Roivant Sciences Ltd. (ROIV)
NASDAQ:ROIV
Want to see ROIV full AI Analyst Report?
ROIV Stock Chart & Stats
$29.83
-$0.41(-3.60%)
At close: 4:00 PM EST
$29.83
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$10.71 - $32.79
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.23M
Market Cap
$22.61B
Enterprise Value$21.13B
Total Cash (Recent Filing)$4.30B
Total Debt (Recent Filing)$107.44M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 17, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding719,270,400
10 Day Avg. Volume5,227,583
30 Day Avg. Volume6,226,649
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue2.56K
Enterprise Value/Gross Profit3.03K
Enterprise Value/Ebitda-80.87
Forecast
1Y Price Target
$36.72Price Target Upside23.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$76.52M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Settlement ProceedsRoivant's sizable cash position plus the $2.25B Moderna settlement materially extends runway and strategic optionality. Low leverage reduces refinancing/dilution risk, enabling sustained R&D and commercial investments, M&A flexibility, or shareholder returns over the next several quarters.
Robust Late-stage Pipeline And Operational ExecutionConsistent, rapid enrollment across diverse indications (dermatomyositis, mosliciguat, IMVT-1402) demonstrates strong trial execution, investigator engagement, and program momentum. This reduces timeline risk and increases the chance of near-term readouts that can convert into durable commercial assets.
High Gross Margins Indicating Scalable Product EconomicsA ~91% gross margin signals that if programs commercialize, product economics could be attractive, supporting sustainable operating margins once fixed R&D and SG&A scale down post-launch. High gross margins are a durable structural advantage in biotech commercialization.
Bears Say
Persistent Cash Burn And Weak Cash GenerationDespite large cash reserves, Roivant's consistent negative operating and free cash flows erode runway absent milestone receipts or asset monetization. Ongoing burn raises dependency on settlements, partnerships or capital markets, constraining long-term capital allocation and heightening dilution risk if deals miss expectations.
Declining Revenue And Persistent Operating LossesMaterial year-over-year revenue decline and deep operating losses indicate the business is not yet generating sustainable commercial cash flow. Continued losses require funding and reduce optionality for reinvestment, making the company reliant on successful program outcomes or non-recurring transactions to reach profitability.
Clinical Interpretability And Endpoint RisksKey efficacy signals derive from open-label data and a randomized-withdrawal design that could fail to show statistical separation despite meaningful clinical benefit. These structural trial design and interpretability risks increase regulatory uncertainty and could delay or complicate approvals and commercial positioning.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was $10.71 and its highest was $32.79 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is $22.61B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on May 20, 2026. The company reported $0.279 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.568.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.3.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 719,270,400 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of $0.279 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went up 14.888%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.72 (23.11% Upside)
$36.72 (23.11% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $29.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.73%
12-Months-Change
Fundamentals
Return on Equity
-6.85%
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong clinical signals (notably the robust open-label 1402 RA responses and mosli hemodynamic activity), solid financial backing (cash of $4.3B and a $2.25B Moderna settlement), and rapid execution across trials and commercial prep. Key risks were acknowledged: interpretability limitations from open-label data, potential difficulty meeting the randomized withdrawal primary endpoint for 1402, some program failures (bitokamab), pending biomarker analyses, and competitive/ regulatory hurdles in indications like CLE and PH-ILD. On balance, the pipeline momentum, cash position, and high-impact data presented outweigh the noted challenges, though important uncertainties remain that will require follow-up data and regulatory feedback.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$36.72
▲(23.11% Upside)
Technical Analysis
Ownership Overview
19.98% Insiders
16.51% Mutual Funds
21.20% Other Institutional Investors
28.05% Public Companies and
Individual Investors